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Patients in the NTI cohort tended to have ‘shorter’ neck. The NTI technique utilized
lesser amount of Thrombin with a trend to a higher success rate and lesser recurrence. The
two patients in the NTI group with recurrent PSA on follow-up imaging study were both
on Coumadin and both PSAs were successfully treated with re-injection of Thrombin. No
serious complications were observed including thromboembolism, limbischemia, aneu-
rysm rupture, or abscess formation.
Conclusion: Femoral pseudoaneurysm closure using the NTI technique is a safe and
efficacious treatment modality. This offers a non-surgical treatment option for PSAs with
morphological features not ideal for the usual STI technique.
NTI
(n  56)
STI
(n  91) P value
Amount of thrombin[IU]
Mean (SD) 994.55 (920) 1501.52 (1384.7) 0.02
Neck length [mm]:
Min; max 0; 2.43 0.13; 3.3
Mean (SD) 0.76 (0.56) 1.06 (0.66) NS
Neck width [mm]:
Min; max 0.1; 2.0 0.1; 2.3
Mean (SD) 0.67 (0.47) 0.78 (0.47) NS
Number of sacs:
1 37 (66.1%) 57 (62.6%)
2 15 (26.8%) 28 (30.8%)
3 4 (7.1%) 6 (6.6%) NS
Success 56 (100%) 87 (96.7%) NS
Recurrence 2 (3.8%) 11 (12.6%) NS
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Background: In the Valentines II trial, the use of second-generation DIOR® paclitaxel
drug-coated balloon (DCB) as adjunct therapy to plain old balloon angioplasty (POBA)
has shown good clinical outcomes in patients with de novo coronary lesions with low rates
of major adverse cardiac events (MACE). We report the quantitative coronary angiog-
raphy (QCA) results of the subset of patients who underwent angiographic follow-up.
Methods: Valentines II trial prospectively enrolled 103 patients with de novo lesions of
50% stenosis who presented with angina and/or documented ischemia on stress testing.
Patients underwent POBA followed by DCB, and in cases of suboptimal angiographic
success additional bail-out stenting was performed. Primary endpoint was MACE at 6-9
months. A subset of patients underwent angiographic follow-up with QCA.
Results: For the study population, MACE, target vessel revascularization and target
lesion revascularization rates were 8.7%, 6.9% and 2.9% respectively. Angiogram was
performed in 35 patients (34%) at mean follow-up of 227  40 days. The QCA results
are shown (Table). Late-luminal loss at follow-up was 0.38  0.39 mm and binary
restenosis was 14.3%.
Conclusion: The result of the Valentines II trial angiographic cohort demonstrates the
efficacy of second generation DIOR® DCB as adjunct to POBA in treating patients with
de novo coronary lesions. This approach achieved low late-luminal loss and binary
restenosis at intermediate-term angiographic follow-up and should be considered for
patients and lesions not suitable for drug-eluting stents.
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Background: The Resolute Integrity zotarolimus-eluting stent utilizes novel continuous
sinusoid technology (CST). With CST, a single cobalt alloy wire is formed into a
repeating sinusoidal pattern, wrapped helically and fused to improve conformability,
provide greater flexibility and ease of delivery without compromising other important stent
design characteristics like radial and longitudinal strength. The objective of the
DELIVER study was to evaluate delivery success as well as in-hospital outcome following
use of the Resolute Integrity stent in an all-comers large patient population.
Methods: DELIVER is a prospective, multicentre, single arm, open-label, observational
study in 163 centers in 33 countries. Patients with coronary artery disease and a lesion of
reference vessel diameter of 2.25 to 4.0 mm were eligible for inclusion. Group 1 received
the Resolute Integrity stent as the first choice of stent treatment and Group 2 were treated
following delivery failure of another stent type. The primary endpoint for the study was
delivery success defined as complete passage of the stent across the target lesion with full
expansion to the desired diameter at the desired location. Other endpoints are in-hospital
clinical outcomes adjudicated by a clinical event committee.
Results: A total of 7740 patients (12165 stents in 10449 lesions) were enrolled between
February 2011 and June 2012. Patients suffered from diabetes mellitus in 34.9% and acute
myocardial infarction 28.4%. Procedure approach was radial in 46.0%, brachial in 0.6% or
femoral in 53.3%. Multiple lesions were treated in 26.9%, pre-dilatation performed in
67.4% and post-dilation in 39.3%. Lesions were de-novo in 94.5% and restenotic in 5.5%.
Type B2/C lesions were treated in 58.8%. Reference diameter pre stent implantation was
2.930.48mm. The primary endpoint delivery success was high with 98.9% [95% CI
98.7-99.1%] in group I and 98.0% [95% CI 89.1-99.9%] in group 2. Adjudicated
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in-hospital events were major adverse cardiac events 1.7% (N128/7740), death 0.3%,
clinically driven target-lesion revascularization 0.1% (N11/7740). Definite and probable
stent thrombosis rate according to ARC criteria occurred in 0.1% (N15/7740).
Conclusions: This largest real-world experience with the new Resolute Integrity stent
platform demonstrated a low in-hospital event rate including a low rate of stent
thrombosis. Delivery success was high with the Resolute Integrity stent as the first choice
of stent as well as after delivery failure of another stent type.
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Background: A higher rate of adverse cardiac events is associated with percutaneous
coronary intervention (PCI) of ostial lesions compared with non-ostial disease. Adjunctive
imaging using intravascular ultrasound (IVUS) during PCI may improve outcomes in
patients with ostial disease. We evaluated the long-term outcomes of patients with ostial
lesions who underwent PCI with and without the use of IVUS.
Methods: From 7/2002 to 8/2010, we retrospectively identified 225 patients with 233 de
novo coronary ostial lesions that underwent PCI with (n  82) and without (n  143)
IVUS guidance. Ostial lesions included native aorto-ostial (left or right main coronary
arteries) or major coronary vessel (left anterior descending, left circumflex, and ramus
intermedius arteries) occurring within 3 mm of the coronary ostium. Clinical outcomes
[cardiovascular death, all-cause mortality, myocardial infarction (MI), periprocedural MI,
target vessel revascularization (TVR), or target lesion revascularization (TLR)] were
compared between patients with and without the use of IVUS using univariate and
propensity score adjusted analyses.
Results: The majority of patients presented with acute coronary syndrome (80%) and
were followed for a mean of 4.2  2.5 years. The predominant ostial vessel location in
both groups was the right coronary artery (37%) followed by the left anterior descending
coronary artery (31%). Aorto-ostial lesions (n  109) comprised 47% of lesions (IVUS:
n 38; no IVUS n 71), whereas the remaining lesions (53%) involved major coronary
vessels (IVUS: n  46; no IVUS: n  78). After propensity score adjustment, IVUS use
was associated with lower rates of the composite of cardiovascular death, MI, or TLR
(HR 0.54, 95% CI 0.29-0.99; p  0.04), composite MI or TLR (HR 0.39, 95% CI
0.18-0.83; p 0.01) and MI (HR 0.31, 95% CI 0.11-0.85; p 0.02) compared with no
IVUS. The use of IVUS was also associated with a trend towards a lower rate of TLR
(HR 0.42, 95% CI 0.17-1.02; p  0.06). Stent under expansion was observed in 40% of
patients who underwent post-stenting IVUS.
Conclusions: The use of IVUS during PCI of coronary ostial lesions is associated with
significantly lower rates of adverse cardiac events.
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Background: Percutaneous mitral valve repair (PMVR) was introduced as an alternative to
the standard mitral valve surgery (MVS) for severe mitral regurgitation (MR). However, the
ideal patient population to benefit from this procedure is still controversial. This study aimed
to identify a potential comparator reference for future percutaneous mitral repair procedures
based on patients undergoing mitral valve surgery stratified by risk groups.
Methods: 422 patients undergoing isolated MVS were divided into 3 risk strata as
defined by the Society of Thoracic Surgeons (STS) score as follows: STS 3 (Low;
n350), STS 3 to6(Intermediate; n36) and STS6 (High; n36). The in-hospital
and 30-day clinical outcomes were compared.
Results: The average age trended higher as the STS increased (p0.05). The incidence
of female sex, diabetes mellitus, hypertension and peripheral artery disease trended higher
with an increase in the STS score. (Table) The 30-day mortality and stroke rates in the
low-, intermediate- and high-risk groups were (0.9%, 11.1% and 13.4%; p 0.001 and
0.9%, 8.3% and 5.6%; p 0.05, respectively).
Conclusions: In a tertiary center, isolated MVS are generally performed in patients with
low STS scores. Patients with a STS score 6 are at high risk for mortality and should
be subjected to a PMVR. The STS score should be used as a comparator tool to evaluate
the performance of PMVR for patients with severe MR.
Baseline Characteristics
Variable
STS<3
(n350)
3<STS<6
(n36)
STS>6
(n36) P value
Age (yearsSD) 54.712.2 66.316.3 70.910.5 0.05
Average STS scoreSD 0.80.7 40.8 11.96.7 0.05
Female 180 (51.4%) 28 (77.8%) 32 (88.9%) 0.05
Diabetes Mellitus 140 (40.0%) 23 (63.9%) 26 (72.0%) 0.05
Hypertension 26 (7.4%) 12 (33.3%) 12 (33.3%) 0.05
%Mitral Valve Replacement 69 (19.7%) 21 (58.3%) 24 (66.7%) 0.05
Outcome at 30 days
Variable Observed
Predicted
by STS
score Observed
Predicted
by STS
score Observed
Predicted
by STS
score p
All-cause-
mortality
3 (0.9%) 0.8% 4 (11.1%) 4% 5 (13.4%) 11.6% 0.05
Stroke rate 3 (0.9%) 10.5% 3 (8.3%) 4.1% 2 (5.6%) 3.3% 0.05
Renal-failure 1 (0.3%) 2.1% 3 (8.3%) 10% 7 (19.4%) 17.3% 0.05
Length of
stay (days)
6.47.1 4.73.5 15.511.4 175.8 20.123.4 32.814.5 0.001
Post
Operative
Atrial-
ﬁbrillation
95 (27.1%) 19 (52.8%) 9 (25%) 0.005
Total
Packed RBC
transfused
(ml.SD)
392.3
963.6
1221.4
1239.3
1596.2
1642
0.001
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Background: Real world data of acute coronary syndrome (ACS) patients who received
intraaortic balloon pump (IABP) remains limited. Therefore, we evaluate the character-
istics of ACS patients who received IABP support from a real world ACS registry.
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